RxDoctor Payments Data

David Eichenbaum, MD

Ophthalmology · St Petersburg, FLNPI 1144251356

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (47.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 54 manufacturers, the largest accounting for just 18.0%. Among ophthalmology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,693,229in general payments, 2019–2025

Across 1,698 payments — averaging $997.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$305K
  • AbbVie$244K
  • Regeneron Healthcare Solutions, Inc.$215K
  • Apellis Pharmaceuticals, Inc.$199K
  • Novartis$165K
  • Genentech, Inc.$84K
  • plus $480K from 48 others
$32,756,069in research payments, 2019–2025

Across 1,989 payments — averaging $16,469 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$12.8M
  • Genentech, Inc.$9.3M
  • Ocular Therapeutix, Inc.$2.1M
  • Roche TCRC, Inc.$1.8M
  • Bayer$1.5M
  • Janssen Research & Development, LLC$1.3M
  • plus $4M from 16 others

What the payments were for

  • Consulting fees$810,26448%
  • Speaking & faculty fees$704,17642%
  • Travel & lodging$111,5907%
  • Food & beverage$44,1503%
  • Education$8110%
  • Gifts$190%
  • Entertainment$1,0560%
  • Ownership interest$20,0131%
  • Other$1,1500%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech USA, Inc.290$304,970
AbbVie(2 entities)251$244,467
Regeneron Healthcare Solutions, Inc.252$215,278
Apellis Pharmaceuticals, Inc.179$198,823
Novartis109$164,938
Genentech, Inc.73$84,266
Astellas Pharma US Inc59$81,222
Ocular Therapeutix, Inc.95$77,243
Eyepoint US, Inc.69$71,542
F. Hoffmann-la Roche AG19$45,799
Regeneron27$25,853
Bausch & Lomb, A Division Of Bausch Health US, LLC24$24,199
Alimera Sciences, Inc.56$23,960
Dutch Ophthalmic, USA27$23,405
Bausch & Lomb Americas Inc.26$21,231
US Retina LLC5$21,162
Bristol Myers Squibb9$11,470
Novartis Pharma AG2$11,275
Roche Products Limited4$8,863
Thrombogenics, Inc.5$5,296
Pfizer1$3,710
Hoffmann-la Roche Limited3$3,273
Harrow Eye, LLC16$3,004
ANI Pharmaceuticals, Inc.13$2,494
AstraZeneca2$2,350
Beaver-visitec International, Inc.1$1,635
Coherus Oncology, Inc.4$1,525
Notal Vision, Inc.2$1,321
Oculus Surgical Inc.3$1,194
Boehringer Ingelheim International GmbH1$950
W. L. Gore & Associates, Inc.1$900
Alcon12$855
Roche TCRC, Inc.3$842
E.r. Squibb & Sons, L.L.C.1$788
Mallinckrodt Hospital Products Inc.21$666
Sanofi US Services Inc.1$441
Natus Medical Incorporated1$337
Sandoz9$278
Amgen(2 entities)3$257
Biogen4$149
Kala Pharmaceuticals, Inc.1$125
Dompe US, Inc.1$122
Ivantis, Inc1$117
Spark Therapeutics, Inc.1$103
Glaukos Corporation1$100
Sanofi-aventis U.S. LLC1$99
Neurotech Pharmaceuticals, Inc.2$75
Carl Zeiss Meditec, Inc.1$70
Celltrion USA Inc.1$41
Samsara Vision1$41
Astellas Pharma Global Development1$36
Alcon Research LLC1$36
Carl Zeiss Meditec AG1$19
Rhythm Pharmaceuticals, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,693,229 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$4,432,051
Medicare patients
902
Services billed
94,790

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProlensaBromfenac Sodium21$7,206
Prednisolone Acetate124$6,667
Lotemax SmLoteprednol Etabonate14$3,491
Dorzolamide-TimololDorzolamide/Timolol/Pf11$1,215
Ketorolac Tromethamine24$713
Atropine Sulfate14$634
Brimonidine Tartrate32$608
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat45$463
Gentamicin Sulfate27$308
Timolol Maleate21$291
Latanoprost14$169

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm$24,199$10,69835 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in St Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →